cmAngio® vs FibriCheck
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your clinical practice aims to integrate cardiovascular risk assessment seamlessly into routine mammography screenings. This AI software is ideal for radiologists and OB/GYN specialists looking to leverage existing mammogram data to identify Breast Arterial Calcifications (BAC) and provide early insights into a woman's cardiovascular health without additional procedures.
View cmAngio® →Choose FibriCheck if…
Choose FibriCheck if you need a convenient, patient-centric solution for remote heart rhythm monitoring and arrhythmia detection. This smartphone-based app is best suited for healthcare providers managing patients with suspected or diagnosed arrhythmias, enabling continuous or intermittent self-monitoring and providing immediate, actionable results for timely intervention.
View FibriCheck →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | FibriCheck |
|---|---|---|
| Pricing | Paid, out-of-pocket | Subscription-based, with options for monthly or annual payments. prices vary by region and may be partly or fully covered by insurance or employer. |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Cloud-based (private cloud). |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
FibriCheckFibriCheck (Tool B) offers a patient-facing mobile application that leverages a smartphone camera for heart rhythm monitoring, making it highly accessible and intuitive for end-users. While cmAngio (Tool A) emphasizes quick installation and DICOM compatibility for clinical workflows, FibriCheck's direct patient interaction via a ubiquitous device suggests broader and more immediate usability for its target audience.
Clinical Value
TieBoth tools offer significant clinical value, addressing different aspects of cardiovascular health. cmAngio (Tool A) provides a novel, non-invasive method to assess cardiovascular risk from existing mammograms, offering proactive insights. FibriCheck (Tool B) delivers real-time detection and monitoring of arrhythmias, including AFib, which is crucial for early intervention and management of active cardiac conditions. Both are FDA-cleared and target critical clinical needs.
Pricing & Value
FibriCheckFibriCheck (Tool B) provides clear, publicly available pricing for both end-users and prescribed patients, including subscription options and expert review costs. This transparency allows for a direct assessment of its value proposition. In contrast, cmAngio (Tool A) requires contacting the vendor for pricing details, making it difficult to evaluate its cost-effectiveness without further inquiry.
Enterprise Readiness
cmAngio®cmAngio (Tool A) demonstrates stronger enterprise readiness through its focus on quick installation, compatibility with any DICOM-compliant viewer, and explicit mention of cybersecurity and HIPAA compliance for integration into existing radiology workflows. While FibriCheck (Tool B) is HIPAA compliant and offers a professional portal, its primary deployment as a patient-facing mobile app suggests a different integration model compared to cmAngio's direct integration into core clinical imaging infrastructure.
Innovation
FibriCheckFibriCheck (Tool B) showcases a more disruptive innovation by transforming a common consumer device (smartphone camera) into a medically certified tool for heart rhythm monitoring, democratizing access to cardiac screening. cmAngio (Tool A) is innovative in extracting new cardiovascular risk insights from existing mammography data, but FibriCheck's approach of leveraging ubiquitous personal technology for direct medical monitoring feels more broadly impactful.
Support & Docs
FibriCheckFibriCheck (Tool B) offers a readily accessible 'Help Center' on its website, including user manuals, FAQs, and specific information for healthcare providers, along with an option for medical expert review. While cmAngio (Tool A) mentions an 'Operator's Manual' in its disclaimers, a quick web search did not reveal a similarly structured and publicly available support portal or extensive documentation as offered by FibriCheck.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | FibriCheck |
|---|---|---|
| Product Name | cmAngiou00ae | FibriCheck |
| Primary Detection Focus | Breast Arterial Calcifications (BAC) on mammograms | Arrhythmias (e.g., Atrial Fibrillation) via heart rhythm monitoring |
| Target User/Application | Healthcare providers for early cardiovascular risk assessment using mammograms | Patients for self-monitoring heart rhythm; healthcare providers for patient monitoring |
| Key Technology/Method | AI software for detecting BAC on Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams | Smartphone camera-based PPG technology with AI-powered algorithm for heart rhythm measurement |
| Specialties | Cardiology, Obstetrics & Gynecology, Radiology | Cardiology, Family Medicine, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and FibriCheck.